340 related articles for article (PubMed ID: 15787963)
1. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
[TBL] [Abstract][Full Text] [Related]
2. Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.
Przydzial MJ; Pogozheva ID; Ho JC; Bosse KE; Sawyer E; Traynor JR; Mosberg HI
J Pept Res; 2005 Nov; 66(5):255-62. PubMed ID: 16218993
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
4. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
6. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
7. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.
Fowler CB; Pogozheva ID; Lomize AL; LeVine H; Mosberg HI
Biochemistry; 2004 Dec; 43(50):15796-810. PubMed ID: 15595835
[TBL] [Abstract][Full Text] [Related]
8. Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.
McFadyen IJ; Sobczyk-Kojiro K; Schaefer MJ; Ho JC; Omnaas JR; Mosberg HI; Traynor JR
J Pharmacol Exp Ther; 2000 Dec; 295(3):960-6. PubMed ID: 11082429
[TBL] [Abstract][Full Text] [Related]
9. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
[TBL] [Abstract][Full Text] [Related]
10. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
11. Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Dolle RE; Michaut M; Martinez-Teipel B; Seida PR; Ajello CW; Muller AL; DeHaven RN; Carroll PJ
Bioorg Med Chem Lett; 2009 Jul; 19(13):3647-50. PubMed ID: 19464172
[TBL] [Abstract][Full Text] [Related]
12. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
13. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
Minami M; Nakagawa T; Seki T; Onogi T; Aoki Y; Katao Y; Katsumata S; Satoh M
Mol Pharmacol; 1996 Nov; 50(5):1413-22. PubMed ID: 8913373
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of novel cyclic alpha-MSH/beta-MSH hybrid analogues that lead to potent and selective ligands for the human MC3R and human MC5R.
Balse-Srinivasan P; Grieco P; Cai M; Trivedi D; Hruby VJ
J Med Chem; 2003 Aug; 46(17):3728-33. PubMed ID: 12904077
[TBL] [Abstract][Full Text] [Related]
15. Substitution of aromatic and nonaromatic amino acids for the Phe3 residue in the delta-selective opioid peptide deltorphin I: effects on binding affinity and selectivity.
Heyl DL; Schmitter SJ; Bouzit H; Johnson TW; Hepp AM; Kurtz KR; Mousigian C
Int J Pept Protein Res; 1994 Nov; 44(5):420-6. PubMed ID: 7896499
[TBL] [Abstract][Full Text] [Related]
16. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
Han G; Haskell-Luevano C; Kendall L; Bonner G; Hadley ME; Cone RD; Hruby VJ
J Med Chem; 2004 Mar; 47(6):1514-26. PubMed ID: 14998337
[TBL] [Abstract][Full Text] [Related]
17. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
19. Helix-inducing alpha-aminoisobutyric acid in opioid mimetic deltorphin C analogues.
Bryant SD; Guerrini R; Salvadori S; Bianchi C; Tomatis R; Attila M; Lazarus LH
J Med Chem; 1997 Aug; 40(16):2579-87. PubMed ID: 9258365
[TBL] [Abstract][Full Text] [Related]
20. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
